

# COST EFFECTIVENESS WORKING GROUP MEETING

## REG Summit 2018

### Minutes

<b>Meeting location</b>	Park Plaza Hotel, Amsterdam Airport
<b>Meeting date</b>	22 <sup>nd</sup> March 2018
<b>Meeting time</b>	17.30-18.30
<b>Chair</b>	Jon Campbell
<b>Attendees</b>	Mike Baldwin, Glenn Crater, Job van Boven, Mohsen Sadatsafavi, Barbara Yawn, Guilherme Safioti, Naomi Lauanders
<b>Objective</b>	<ul style="list-style-type: none"> <li>Brainstorm new ideas for projects and determine the best way to fund projects in this working group.</li> </ul>

#### Minutes:

	<p><b>Brainstorming</b></p> <ul style="list-style-type: none"> <li>Possibility of working with other REG working groups.</li> <li>There is a need to promote to the other working groups, but also to HEOR within the pharmaceutical industry – who are the likely sponsors?</li> <li>Need to define a first REG project and build from there.</li> </ul> <p><b>Potential ideas:</b></p> <ul style="list-style-type: none"> <li>Cost effectiveness of a pathway e.g. time to triple therapy paper. Funders want to know what is the optimum, but what are we optimizing on?</li> <li>Mohsen's COPD modelling work – generic economy model for COPD. Possibility to expand outside of Canada.</li> <li>Use of OPCRD to validate model assumptions. Select patients and assess model projections compared to patient outcomes.</li> <li>Disinvestment of COPD. Potential for looking at the economic impact of COPD in non-smokers? Possibly in two different databases, with differing populations (Taiwan?). Unlikely to get occupation data, but is it possible to link to environmental factors based on postcode/area code data?</li> <li>Predictive mortality in COPD compared with myocardial infarction. Mortality after first MI compared with first exacerbation. There is already a paper on this.</li> <li>Predicting future burden of COPD by combining evidence on its current burden with projection of population growth and aging and smoking trends across multiple jurisdictions</li> <li>Uncontrolled asthma and model age projections for burden over time. Review published data.</li> <li>Distribution of costs in subgroups of the population.</li> <li>Use of novel data sources e.g. FitBit.</li> </ul>
--	---

	<p><b>Prioritisation</b></p> <ul style="list-style-type: none"><li>○ Focus on cost of COPD in non-smokers</li></ul>
<p><b>Actions from WG meeting</b></p>	<p>REG to circulate proposal proforma. Job van Boven to lead on the creation of a proposal for the cost of COPD in non-smokers</p>